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a b s t r a c t 
This research evaluates reconﬁguration opportunities in Pharmaceutical Supply Chains (PSC) resulting 
from technology interventions in manufacturing, and new, more patient-centric delivery models. A critical 
synthesis of the academic and practice literature is used to identify, conceptualise, analyse and categorise 
PSC models. From a theoretical perspective, a systems view of operations research is adopted to pro- 
vide insights on a broader range of OR activities, from conceptual to mathematical modelling and model 
solving, up to implementation. 
The research demonstrates that: 1) current deﬁnitions of the PSC are largely production-centric and 
fail to capture patient consumption, and hence healthcare outcomes; 2) most PSC mathematical models 
lack adequate conceptualisation of the structure and behaviour of the supply chain, and the boundary 
conditions that need to be considered for a given problem; 3) models do not adequately specify current 
unit operations or future production technology options, and are therefore unable to address the criti- 
cal questions around alternative product or process technologies; 4) economic evaluations are limited to 
direct costing, rather than systemic approaches such as supply chain costing and total cost of ownership. 
While current models of the PSC may help with the optimisation of speciﬁc unit operations, their 
theoretical beneﬁts could be offset by the dynamics of complex upstream (supply) and downstream (dis- 
tribution and healthcare delivery) systems. To overcome these limitations, this research provides initial 
directions towards an integrated systems approach to PSC modelling. This perspective involves problem 
conceptualisation and boundary deﬁnition; design, formulation and solution of mathematical models, 
through to practical implementation of identiﬁed solutions. For both academics and practitioners, re- 
search ﬁndings suggest a systems approach to PSC modelling can provide improved conceptualisation 
and evaluation of alternative technologies, and supply network conﬁguration options. 
© 2017 The Authors. Published by Elsevier Ltd. 
This is an open access article under the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
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i  1. Introduction 
With access to essential medicine being one of the build-
ing blocks of healthcare systems [1] , policy measures aimed at
reducing healthcare spending growth at the international level
have targeted primarily the pharmaceutical industry, over the
past decade [2] . In the UK, the healthcare system ranks higher
for spending than for health outcomes [3] , and pharmaceutical
products have contributed to the lower end of manufacturing
gross value added growth since 2010 [4,5] . At the same time,
traditional pharmaceutical manufacturing is being challenged by
emerging requirements, such as greater drug product personal-
isation, more participative healthcare enabled by the adoption
of digital information and communication technology [6] , and∗ Corresponding author. 
E-mail address: E.Settanni@eng.cam.ac.uk (E. Settanni). 
a  
t  
m
http://dx.doi.org/10.1016/j.orp.2017.05.002 
2214-7160/© 2017 The Authors. Published by Elsevier Ltd. This is an open access article uy the advancement of innovative technology interventions such
s continuous manufacturing, which promise to achieve smaller
ootprints and greater responsiveness [7,8] . 
While these challenges have received greater attention in the
ainstream business and engineering literature, it is still open
o discussion whether, and to which extent, current approaches
o PSC modelling adequately reﬂect and address such challenges.
esearch is now paying greater attention to the interdependences
etween Pharmaceutical Supply Chains (PSC) and the broader
ealthcare bundle [9] . Coordination between actors, and inventory
anagement are still perceived to be the primary challenges in
trengthening global health pharmaceutical delivery, however,
he deployment of sophisticated inventory models is deemed
nsuﬃcient per se to improve the current situation [10] . Novel
pproaches must be deployed to achieve greater “end-to-end” in-
egration along the PSC through technology advances in medicines
anufacturing and more patient-centric delivery models [7] . nder the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
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Fig. 1. Evaluation grid based on [15] . 
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o  The research presented in this paper aims to inform the debate
n how to evaluate the multifaceted aspects of PSC reconﬁguration
pportunities enabled by technology interventions in medicine
anufacturing, as well as more patient-centric delivery models.
o do so it provides a critical synthesis of the state-of-the-art
pproaches commonly employed in the academic literature and
ndustry practice to identify the relevant aspects of a PSC; to
onceptualise those aspects through visualisation; and to quan-
itatively evaluate them. The following research questions are
herefore addressed: 
(1) “What is meant by PSC for modelling purposes?” (deﬁni-
tion); 
(2) “How is a PSC conceptualised through visualisation?”
(conceptual models); 
(3) “Which aspects of a PSC are expressed quantitatively, and
how”? (mathematical models). 
Gaps are identiﬁed by comparing and contrasting the char-
cteristics of a PSC, which are currently modelled, with those
hat should be considered in a context where reconﬁgurations
pportunities are being targeted, such as in [8] . 
The scope of this paper does not aim to include any type of
odels outlined to investigate a PSC. Models may be used, among
ther things, to rank multiple decision-making criteria, or estab-
ish statistical relationships between constructs as, for example, in
urveys [11] . In line with the theoretical viewpoint taken by Carter
t al. [12] it is, therefore, useful to distinguish between models for
he advancement of theory building in supply chain management
nd models that contribute to the advancement of theory building
n what is purportedly managed—the supply chain itself. The latter
s the focus of this paper. 
The paper is structured as follows. Section 2 sets out the
erminology, materials, and methods. In Section 3 synthesising
rguments are derived from the analysis of the literature to
haracterise archetypal PSC models. Theoretical and practical
mplications of each archetype are discussed in Section 4 . Section
 provides concluding remarks, and directions for future research. 
. Materials and methods 
The rationale of a synthesis process is to achieve of a coherent
onceptual structure of a topic, using the extant literature as the
bject of scrutiny [13,14] . The terminology, theoretical lenses,
ethods and materials relevant to this research are speciﬁed in
he following sub-sections. 
.1. Basic terminology 
As the focus of this research is modelling, it is necessary to
eﬁne what is meant by a ‘model’ in this context. 
In such ﬁelds as Operations Research (OR) how the analyst
onstructs a mental image of a problematic situation is often
eglected. The analyst develops such an image by an act of
ppreciation from unorganised perceptions acquired through obser-
ation, and proceeds from such an image to formally represent the
ituation in symbolic terms [15] . Making reference to industrial
ystems Forrester [16] points out that models represent only
hat the analyst believes to be the nature of the system being
tudied, and each model is eventually shaped by a speciﬁc class of
uestions about such systems. 
Conversely, a signiﬁcantly high proportion of Supply Chain and
perations Management (SC&OM) research promotes a view of the
esearcher as tasked with discovering cause-and-effect relation-
hips within an objective reality from which they postulate to de-
ach themselves [17] . A common narrative in SC&OM is that an op-
rations model is a miniature representation of a supply chain [18] ,nd the extent to which a model differs from the ‘real thing’, is a
atter of comprehensiveness [19] . Insofar as suﬃcient quantitative
ata is available to populate a mathematical model, the problem
ituation is assumed to be well deﬁned, and modelling a supply
hain becomes a matter of implementing speciﬁc analytical tools
20–22] ). This assumption is implicitly made in most models of
ealthcare systems [23] , and pharmaceutical manufacturing [24] . 
Based on Wilson’s [25] work on the analysis of organisation
nits a model is deﬁned here as an intellectual construct explicitly
escribing a way of thinking about the real world. A model so
eﬁned acknowledges the perspective taken by an analyst who is
aking sense of a situation to reach a value judgment about it. 
.2. Theoretical lens 
This paper adopts the systems view of OR, outlined by Sagasti
nd Mitroff [15] , as the theoretical lens, hereafter referred to as
he Sagasti–Mitroff research model. Although without explicit 
eference to supply chain modelling, the Sagasti–Mitroff research
odel captures generic aspects of the modelling activity, and it
as previously informed methodological discussions in the SC&OM
omain [19] . 
The fundamental dimensions to evaluate numerical and non-
umerical aspects of PSC models proposed in the extant literature
ere derived from the Sagasti–Mitroff research model as shown in
ig. 1 . 
Unlike the original Sagasti–Mitroff research model, Fig. 1 does
ot identify a conceptual model with the analyst’s own mental
mage of the problem situation. Rather, a conceptual model is
nderstood here to be a description involving some degree of
ormalisation, for example in the form of supply network maps
26] ; rich pictures [25] ; and process diagrams [27] . 
.3. Synthesis approach 
Typically, the literature provides non-numeric evidence as it
onsists of words and symbolic data (e.g., text and equations).
n the ﬁeld of SC&OM the approach to content analysis, outlined
y Seuring and Gold [28] , is amongst the most explicit in terms
f data gathering and data analysis, and has been used in works
hat explicitly take a supply chain modelling outlook (for example,
29,30] ). Other works with a similar outlook tend to be less
peciﬁc regarding the adopted approach for example [31,32] ). 
Methods for evidence-based research synthesis originally devel-
ped in healthcare research include, for example, Critical Interpre-
76 E. Settanni et al. / Operations Research Perspectives 4 (2017) 74–95 
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stative Synthesis (CIS), and aim to generate knowledge that goes be-
yond the conventional literature reviews by placing heterogeneous
evidence in a coherent framework so that tensions and contradic-
tions are exposed [33] . Tranﬁeld et al. [14] discuss in-depth the
advantages and limitations of extending the methods for evidence-
based research synthesis developed in medical research to the
management domain. In this research, CIS is used to generate syn-
thesising arguments, through an interpretative process, which inte-
grates quantitative and qualitative evidence from a heterogeneous
body of knowledge, while explicitly questioning assumptions about
the concepts and methods by which different solutions are derived.
Both primary and secondary research is the object of scrutiny
in this paper. To enable content search the deﬁnition of ‘modelling’
provided in Section 2.1 was operationalised by including more
specialised terms such as ‘mathematical programming’ and ‘simu-
lation’, as well as more generic terms such as ‘design’ and ‘analy-
sis’. The following query was formulated to content search Web of
Science for secondary research with an explicit supply chain mod-
elling outlook, without restricting it to speciﬁc PSC applications: 
((“supply chain” OR “supply network”) AND review AND
(Optim ∗ OR simulation OR model ∗ OR programming OR design OR
analysis)) 
The search was limited to contributions written in English,
published in peer-reviewed journals from 1998 (to coincide with
the seminal review by Beamon [34] ) in the following research
areas: engineering, business economics, operations research, man-
agement science, computer science, and environmental sciences.
The search initially generated 1744 results in Web of Science, of
which 231 passed a ﬁrst screening considering title, abstract and
keywords to ensure that the point of focus was the use of models
in SC&OM. Of these references, nine were speciﬁcally concerned
with pharmaceutical and healthcare related issues, with two
[9,35] used as a source of references for primary research. The
publications retained are summarised in Table 1 . 
Primary research was identiﬁed over the last 5 years through a
similar search query: 
((“supply chain” OR “supply network” ) AND pharm ∗ AND
(Optim ∗ OR simulation OR model ∗ OR programming OR design OR
analysis)) 
The reﬁned search yielded 232 research papers, 38 of which
were retained and expanded with 27 papers obtained from the
selected reviews. Two references not included in the structured
search were also added, one of which was a technical report. A
total of 76 references were systematically collected through the
reference management and knowledge organisation software Citavi
4 ( www.citavi.com ). Categories were initially derived from the sec-
ondary literature, and then modiﬁed and reﬁned through the CIS
approach as the analysis progressed to better reﬂect the emerging
themes. From a procedural perspective, Citavi was used to assign
categories to references as a whole, as well as to individual textual
excerpts to allow retention of the meaning for text once it was re-
moved from the context of speciﬁc studies, and in order to perform
a meta-data-analysis [36] . A detailed classiﬁcation of each research
paper examined here is provided in Appendix A , Tables A .2 –A .3 . 
3. Research ﬁndings 
In this section, extant PSC models are evaluated in terms of
their ability to enhance the analyst’s understanding of the inher-
ent characteristics of the speciﬁc system of interest [16] . For each
research question outlined in Section 1 , evidence is gathered from
the literature on PSC models, consistent with a systems view of
the OR activity ( Section 2.2 ). A series of synthesising arguments
are then formulated in Sections 3.1 –3.4 . .1. Synthesis of PSC deﬁnitions 
Previous studies conceptualise the PSC as a ‘complex adaptive
ystem’, and use such a concept as the object of empirical research
37] . This view echoes a more general tendency to acknowledge
upply chains operate ‘as a system’, and hence should be con-
eptualised, modelled, and managed as such [12] . In particular,
he supply chain is a system which encompasses elements and
elationships that are socio-technical in nature [38] . 
The concept of Healthcare Delivery System (HDS) captures
he broader ecosystem in which a PSC operates. According to
he World Health Organization (WHO) an HDS consists of the
rganisations, institutions, resources, and people engaged in the
quitable and eﬃcient delivery of services that are critical to
chieve an improved health status, whereby ‘health’ is not merely
he absence of disease or inﬁrmity [1] . Along with other medical
upplies, the PSC contributes to the ability of an HDS to ultimately
eliver healthcare service outcomes so long as medicines are
vailable, affordable and safe [9] . 
To summarise, in principle the PSC is a socio-technical system
imed to align ﬁrms in enabling the achievement of improved health
tatus through medicine s provision. Complementary and alternative
roducts and process technologies may coexist within such a system. 
In practice, the most common approach in deﬁning the PSC for
odelling purposes is to ‘follow the pill’: in 80% of the reviewed
eferences (henceforth, percentages refer to these references unless
therwise speciﬁed) the concept of supply chain is either implicit
r it designates a more or less detailed breakdown of sequential
ctivities (also echelons or stages) centred on the individual drug
roduct as it progresses from its development stage to its ﬁnal
elivery (for example, [35] ). A typical breakdown spans from drug
anufacture until it reaches the point of dispensing to patient
57%); it rarely extends upstream to include raw materials (8%);
ften, boundaries are narrowed to include only the manufacture
f Active Pharmaceutical Ingredients (API) and dosage forms
19%). Works that investigate the contribution of a PSC toward
he achievement of some level of service to the patient through
ealthcare operations are also product-centric, since the provision
f a ‘service’ is typically a synonym for a stock availability [39] . 
None of the examined deﬁnitions seem to provide a ‘whole
ystem’, end-to-end perspective on pharmaceutical supply net-
orks, which is necessary to evaluate emerging reconﬁguration
pportunities arising from a changing healthcare ecosystem [7,8] .
roadly speaking, a system must involve a combination of inter-
cting discrete elements, which may be of a technical or social
ature, organised in a structure ﬁt to achieve some purpose [40] .
hese system-qualifying aspects can be found in most deﬁnitions
f supply chain (see, for example, [41] ). However, only 23% of the
xamined deﬁnitions explicitly state some speciﬁc purpose for the
SC (‘alleviate suffering’; ‘carry out a clinical trial’ or ‘ensure suﬃ-
ient drugs for a clinical study’), and even less (13%) make a claim
bout its nature as a whole (namely a ‘system’; an ‘integration
rocess’). This leads to the following synthesising argument: 
Synthesising argument 1: The PSC is mostly identiﬁed as a
product-centric, linear sequence of stages which spans across
the manufacture and physical distribution of medicines. 
With regards to the context in which a deﬁnition of PSC is
rovided, research papers focus alternatively on new products
eing developed and tested, clinically trialled or commercialised,
nd this speciﬁcation undoubtedly has practical relevance [42] .
owever, the conceptual deﬁnitions reviewed were deemed sim-
lar with regards to building blocks, links, scope and boundaries
egardless of which type of context engages the underlying PSC. A
imilar reasoning applies to the case of emergency humanitarian
upply chains [43] . 
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Table 1 
Literature reviews on pharmaceutical supply chain (PSC) with a modelling outlook. 
Reference Review Scope Models reviewed Key concepts 
New Product 
Develop 
Clinical trial 
supply chain 
Drug product 
Manuf. 
Distribution/Retail Conceptual Scientiﬁc Solvers Clinical trial 
supply chain 
Pharmaceutical 
supply chain 
Pharmaceutical 
enterprise 
Healthcare 
supply chain 
Emergency 
supply chain 
Exclusively PSC 
[35] ● ● ● ● ● ● ● ●
[9] ● ● ● ● ● ● ●
[90] ● ● ● ● ● ● ●
[97] ● ● ●
PSC in a broader context (healthcare/process industry) 
[98] ● ● ● ●
[43] ● ● ●
[52] ● ● ● ●
[99] ● ● ● ●
[100] ● ● ● ● ● ● ●
[101] ● ● ● ● ●
78 E. Settanni et al. / Operations Research Perspectives 4 (2017) 74–95 
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 3.2. Synthesis of PSC conceptual models 
Conceptual models of the PSC describe which phenomenon
is of interest for the analyst, typically by use of a graphical
representation. With speciﬁc reference to PSC, Srai et al. [7] ap-
ply supply chain mapping techniques to support an end-to-end,
whole-system-level evaluation of PSC reconﬁguration opportunities
enabled by speciﬁc technology interventions. Seldom is the con-
ceptual modelling of a system acknowledged as a rigorous mod-
elling activity, and hence the diﬃculty in distinguishing the system
of interest from its surroundings tends to be underestimated [44] . 
To summarise, in principle the identiﬁcation and representation
of the system of interest within a PSC is an explicit and formalised
activity aimed to delimit the areas of concern for the analyst by
deﬁning the scope and boundaries for the problem situation . 
Conceptual models were evaluated for 63 of the 67 research
papers originally selected (4 were deemed out of scope after
closer examination). The phenomena most represented by means
of a PSC conceptual model include: distribution topologies (28%
of cases); multi-facility production systems (23%); and workﬂows
within individual facilities (25%). Fewer conceptual models rep-
resent organisational behaviours within the industry (11%); and
Information Technology infrastructures (5%). 
A PSC was modelled conceptually by means of diagrammatic
‘nodes-and-arcs’ structures in 83% of cases. However, only 22%
follow a formalised technique to outline such diagrams. Examples
include techniques developed in the domain of Process Systems
Engineering, such as State-Task-Networks (STN) and process dia-
grams, or System Dynamic’s causal loop diagrams. However, causal
loop diagrams represent connections between variables identiﬁed
within the formulation of a mathematical problem rather than
between the elements of a PSC. Conceptual models of digital
infrastructures are the subject of a specialised type of diagram-
matic representation, employed to explore the implementation
of speciﬁc solutions, for example, inventory management across
the PSC [45,46] , and the tracking of counterfeit drug products[47].
In all the other cases, the meaning attributed to the nodes and
arcs in a diagrammatic representation is left to the researchers’
discretion, and hence varies signiﬁcantly across studies. 
Other approaches are used to represent the broader ecosystem
of a PSC. Compton et al. [23] use an unstructured pictorial rep-
resentation to model the elements of a HDS: patient, care team,
organisation, and political and economic environment. Although
without declaring it explicitly, Yang et al. [48] use a ‘rich picture’
to illustrate the application of printed electronics in intelligent
medicine packaging to collect health data through a homecare
platform. 
Finally, an often-overlooked aspect of conceptual modelling is
whether, and to which extent, the outlined model is underpinned
by a rigorous collection and analysis of qualitative data. In 77%
of the selected items this aspect is omitted. Only 11% of cases
mention the analysis of qualitative data elicited from survey
respondents or interviewees as part of the research methodology.
However, when the emphasis is placed on mathematical modelling
the use of qualitative data analysis, if any, is largely undisclosed.
Exceptions include works such as [49] and [50] , which are based
on System Dynamics; and [51] , where a fully-speciﬁed case study
research underpins the formulation of a mathematical model of
the PSC. 
This leads to the following synthesising argument: 
Synthesising argument 2 : Most conceptual models of the
PSC consist of loosely formalised diagrammatic representations
of heterogeneous objects of analysis, such as whole organi-
sations; distribution topologies; digital infrastructures; multi-
facility production systems, or workﬂows within individual fa-cilities. Occasionally, such diagrammatic representations are un-
derpinned by qualitative data analysis. 
.3. Synthesis of PSC mathematical models 
End-to-end analysis of the PSC ‘as a system’ is crucial to inform
n integrated system re-conﬁguration agenda. This enables the
dentiﬁcation and assessment of the key metrics that quantify the
otential repercussions of targeted transformation scenarios [7,8] .
athematical models are formalised through a language deemed
ess ambiguous and can be manipulated to generate solutions
15,16] . In particular, a mathematical model of the PSC should enable
he analytical evaluation of its current and alternative states in terms
f structural and behavioural characteristics, in response to changes
n market demands, patient needs, and resources availability . 
Existing classiﬁcations focus more on model-solving techniques
han on PSC models per se (for example, [52] ). Mathematical
odels of the PSC were identiﬁed by examination of the equations
eported in the reviewed items, if any. In the majority of cases a
odel of the PSC was embedded in mathematical programming-
ype models meant to optimise some ﬁgure of merit, such as in
roduction-delivery system planning [32] , strategic game-theoretic
odels [53] , and statistical Data Envelopment Analysis [54] . These
roader models share a similar constrained optimisation intent,
espite being typically assigned to distinct categories (for example,
29] ). 
Detailed PSC models from 50 items were synthesised, after ex-
luding some items due to lack of relevant mathematical contents,
r because saturation was reached. These models were grouped
ccording to “archetypes”, derived by CIS, rather than enumerated
ccording to the modelling approach claimed. Each archetype is
iscussed separately in the following Sections 3.3.1 –3.3.3 . 
.3.1. Archetype I: supply and demand matching mechanism 
Approximately 54% of mathematical PSC models presented in
he reviewed references represent a supply and demand matching
echanism within a multi-echelon production-inventory system,
enceforth referred to as Archetype I. 
The key features exhibited by mathematical PSC models syn-
hesised here as Archetype I can be summarised as follows, using
55] as a case exemplar for illustrative purposed: 
• One or more discrete “slices” are taken along the time axis. In
the example, time slices are 1-month long time periods over a
1-year long time horizon. 
• Within a time slice, a set of elements and links between
such elements are identiﬁed according to speciﬁed scope and
boundaries. In the exemplar case, the boundaries correspond
to a single manufacturing site, within which three distinct
business units operate, each one specialised in a dosage form
manufacturing and packing. The scope includes each activ-
ity/task performed by each piece of equipment; the material
conversions taking place in each business unit to bring about
a range of products; the purchase of raw materials or extra
capacity if needed, and the sale of ﬁnished products. 
• The links between elements included within the boundaries
and described to a level of granularity consistent with the
scope are logical relationships of technological or chronological
precedence. In the exemplar case, the activities are linked
through material ‘input–output’ relationship deﬁned by the
relative amounts of materials required or resulting from a
reference unit of activity level (one ton of product)—also called
‘technological coeﬃcients’. The utilisation of operant resources
such as equipment by activities is also expressed through a
coeﬃcient called activity-facility ratio. 
E. Settanni et al. / Operations Research Perspectives 4 (2017) 74–95 79 
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dependencies from 
previous me periods
dependencies from 
other producon-inventory
systems
dependencies from 
the natural environment
deliveries to
future me periods
deliveries to other 
producon-inventory
systems
environmental 
intervenons
System boundaries and scope
Time horizon
Fig. 2. Synthesised model of the PSC as an inter-temporal demand–supply matching mechanism within a production-inventory system. Table 3 provides details on the 
notation used. 
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i  • While some aspects of the modelled PSC are known, other
aspects need to be determined by means of computation. In
the exemplar case, the technical coeﬃcients are known and
remain unchanged over time, but the level at which each activ-
ity must operate, and the ﬁnal inventories in each time period
are unknown variables. The resulting network conﬁguration is
therefore ﬁxed, as the main unknown is the strength of the
links between the PSC elements, not whether such links exist. 
• In general, input–transformation–output structures are under-
pinned by technological knowledge [56] , which may or may not
be addressed explicitly in a mathematical model. The example
does not specify the modelled products, materials and manu-
facturing technologies (such as batch or continuous), although
some of the manufacturing steps are mentioned explicitly, and
so are the dosage forms. 
The above mentioned features can be formalised concisely
hrough a set of vectors, matrices and basic algebraic operations
onnecting them. The suggested formalised representation of
rchetype I models is illustrated Fig. 2 and Table 2 and discussed
elow. 
Quantiﬁed dimensions of the PSC: The dimensions of a PSC
epresented in a mathematical model (such as time periods,
ocations, equipment, activities, materials) are often organised
ierarchically, and captured in the equations through a number
f indexes that vary from study to study. With reference to the
eviewed models the following was found: 
• The columns in matrices U and V (rows in vector s) reﬂect a
combination of sites/locations (85% of the reviewed models),
time periods (75%), tasks/activities (35%), geographies (32%),
scenarios (25%), and campaigns (14%). 
• The rows in matrices U, U p and V (and in vectors b, d, and f)
reﬂect a combination of product categories such as raw ma-
terials, ﬁnal products and intermediates (97% of the reviewed
models). Further distinctions include, for example product
families and compound stability classes (14%). • The rows in matrix U c typically reﬂect types of manufacturing
equipment or storage facilities, and the capacity which is being
utilised (35% of the reviewed cases). 
• The rows in matrices V e and U e are often of little or no rele-
vance. The possibility of a drug product turning into waste, for
example, if unused at the end of a clinical trial or if a change
in policy and legislation occur is considered in 21% of the
reviewed models. However, a detailed identiﬁcation of environ-
mental resources utilised (for example water), and pollutants
released into the natural environment (for example carbon
dioxide) is limited to models that are speciﬁcally developed in
the domain of environmental Life Cycle Assessment, such as
[57] . 
• Lead times in production, forming the entries of vector τ ,
are speciﬁed in almost 60% of cases. Lead times mostly refer
to clean ups and set ups, especially in models where data
is speciﬁed by “campaign”, which is a characteristic of batch
manufacturing. 
Known parameters and variables to be computed: The main
arameters that must be known in Archetype I PSC models are
he preconditions and post conditions that must be observed in
roduction, or technical dependencies. These are often expressed
n terms of input linkages captured by the elements in matrices
, U p , U c , and U e ; and output linkages captured by the elements
n matrices V and V e . In 39% of the reviewed models the mag-
itude of these technical dependencies is given as a “cookbook
ecipe”, an example of which are the technological coeﬃcients in
55] . In 36% of cases, matrices U and V only contain ones and ze-
os, implying that the amount of product delivered at one echelon
f the PSC is entirely transferred to another (for example, [51] ).
n most Archetype I models, an exogenous demand f summaris-
ng patient consumption, is also known or knowable. Conversely,
he main variables to be determined are the elements of vector
, which represent whether the corresponding transformation step
s performed and, if so, at which level it should operate. In 4% of
8
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Table 2 
Explanation of matrices and vectors used to represent purposeful transformations in Archetype I. 
Notation Description Represented aspect Rows Columns Generic element 
Temporal and downstream decoupling 
b Vector of beginning inventories 
at time t 
Dependencies from previous time 
periods 
Endogenously supplied and used 
inputs/outputs (e.g., 
intermediate and ﬁnal 
products), indexed as 
i = 1 , . . . ,n ∈ N 
N/A b i ≥ 0 Amount of ‘operand’ resource i available 
at the beginning of the time period 
considered, expressed in appropriate 
units 
d Exogenous demand vector Deliveries to other economic 
systems 
As above N/A d i ≥ 0 Non-controllable demand forecast to be 
met through the system’s ﬁnal 
deliveries. 
f Final inventory vector Deliveries to other time periods As above N/A f i ≥ 0 Amount of i available at the end of the 
time period considered 
Level of activity 
s Activity level vector System behaviour Transformations deﬁned 
according to the technological 
knowledge available and the a 
level of granularity, indexed as 
j = 1 , . . . ,n ∈ N 
N/A s j ≥ 0 Level of activity of each transformation 
stage e.g., product volume; 
selection/not selection of a speciﬁc 
transformation etc. 
Technological dependencies 
U Technological pre-conditions 
(inputs) 
Within-boundaries structural 
dependencies between 
purposeful transformations 
As above Purposeful transformations characterised 
according to the technological 
knowledge available and the desired 
level of granularity, indexed as 
j = 1 , . . . ,n ∈ N 
u ij ≥ 0 Amount of ‘operand’ resource i to be 
acted upon for producing an effect by 
executing j , expressed for a reference 
level of activity of j (for example, one 
unit of output, one operating hour, one 
time period) 
V Technological post-conditions 
(outputs) 
As above As above As above v ij ≥ 0 Amount of i delivered by an accomplished 
execution of j at a reference level of 
activity 
U p Transactions with exogenous 
suppliers 
structural dependencies with 
transformations outside the 
system’s boundaries 
Inputs not provided by any 
transformation within the 
system boundaries (e.g., raw 
materials, energy), indexed as 
i = n + 1 , . . . , n II ∈ N 
Purposeful transformations characterised 
according to the technological 
knowledge available and the desired 
level of granularity, indexed as 
j = 1 , . . . ,n ∈ N 
u 
p 
i j 
≥ 0 Amount of ‘operand’ resource i to be 
acted upon for producing an effect by 
executing j , expressed for a reference 
level of activity of j 
U c Asset utilisation As above Durable inputs not provided by 
any transformation within the 
system boundaries (e.g., 
equipment, personnel) indexed 
as i = n II + 1 , . . . , n I I I ∈ N 
As above u c 
i j 
≥ 0 ‘operant’ resources, employed to act upon 
the ‘operand’ resources throughout 
multiple executions of j , expressed for a 
reference level of activity of j 
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s  ases, both the presence or absence of technical dependencies, and
he magnitude of such dependencies, are variables to be simulta-
eously determined by solving the model (for example, [58] ). In-
entory levels at the beginning and end of each time period, repre-
ented by vectors b and d, are also unknown variables that must be
omputed. In 25% of cases the focus is shifted away from manufac-
uring, and towards multi-echelon inventory systems where most
ctivities relate to replenishing inventories of pharmaceutical prod-
cts (for example, [59] ). However, some inventory models focus
xclusively on known demand and cost parameters, rather than
n the technical and temporal dependencies between the activities
aking place in a PSC, when computing variables such as the ‘op-
imal’ order quantity and reorder points [39,42] . Technical depen-
encies in production are mostly omitted also in models that focus
n behavioural aspects of organisations (for example, [53,60] ), or
nvestment decisions (for example, [61] ). In all these cases the in-
ut structure (matrix U) is typically irrelevant, whereas the dimen-
ions of matrix V and vectors, b, d, s and f reduce to one ﬁnished
roduct, multiple time periods, and possibly multiple locations. 
Inclusion of time in the computations: With regards to tem-
oral dynamics, in 60% of Archetype I models two consecutive time
lices are connected by ‘moving’ inventories from one period to
he next. In 25% of the models, time plays no role since the focus
s on a ‘static snapshot’ of a PSC over a pre-deﬁned time horizon
ith no analytical linkages to past or future periods. Conversely,
5% of the models are time-lagged, meaning that the presence
f non-zero lead times (vector τ) in production creates linkages
cross non-adjacent time slices (for example, [51] ). In some cases
ime lags are due to the expansion of production capacity, as in
ew plant construction [61] or to the speciﬁcation of shelf life
or individual materials and products [62] . Non-manufacturing
odels of the PSC are mostly concerned with determining optimal
eplenishment and safety stocks ahead of a planning horizon, and
herefore do not necessarily depict how production and inventories
nfold dynamically over time (for example, [42] ). 
Disclosure of technological knowledge about products, man-
facturing and digital technologies: Almost all the Archetype I
odels reviewed are not affected by the underpinning product
nd manufacturing technology. In 52% of the reviewed papers
anufacturing technology is generically described as batch (37%),
ontinuous (7.41%), or both but has no immediate repercussion on
he mathematical model formulation (for example, [58,61] ). Only
ne Archetype I model makes the case for the introduction of a
igital Information Technology to improve inventory management
n home healthcare provision [63] . 
In summary, this leads to the following synthesising argument: 
Synthesising argument 3(a) : Most models represent the be-
haviour of a PSC as a mechanism to align supply and de-
mand of medicines and related materials across a multi-echelon
production-inventory system, where the structure of such a sys-
tem is deﬁned in terms of technical and temporal dependencies.
Typically, the patient’s condition is outside the boundaries of a
PSC, and the technology interventions in manufacturing and in-
formation management remain implicit. 
.3.2. Archetype II: generalisation models 
Archetype II models make up 8% of the reviewed cases. This
rchetype includes models in which some operational aspects of
 PSC are evaluated by means of generalisations obtained through
tatistical associations or subjective judgment. They typically are
imed at overcoming a detailed, mechanistic modelling of a PSC
rom ﬁrst principles, which is a characteristic of Archetype I.
eing computationally heterogeneous, Archetype II models will
e discussed case-by-case, rather than by attempting a synthesisf a common underpinning mathematical formulation as in the
revious section. 
Most Archetype II models are data-driven, meaning that they
im to “make sense” of an existing track record of empirical
vidence by ﬁtting some exact mathematical approximation to
t. Typically, these data-driven models yield a ‘summary statis-
ic’ which quantify a speciﬁc aspect of a PSC echelon based on
vailable data. For example, Kumar et al. [64] describe a number
f medicine distribution and dispensing business units in terms
f historical data about expenditure and sales over multiple time
eriods. The eﬃciency of inputs utilisation at each unit and at dif-
erent points in time is then computed by solving a mathematical
rogramming model which is characteristic of Data Envelopment
nalysis (DEA). Another application relies on data across a number
f API manufacturing batches to generalise by statistical inference
he relationship between informative manufacturing parameters 
nd cumulative energy consumption [65] . Batch manufacturing
ata also provide the basis to estimate variability in lead times as
 probability density function with unknown parameters [66] . 
A somehow different kind of Archetype II model is one in
hich the empirical data gathered consists of subjective judg-
ents, for example in the form of scores given by experts on the
elative importance of certain aspects of the PSC. Example range
rom hypothesised severities of hazards occurring due to tainted
r counterfeit drugs [67] , to the application of Analytical Hierarchy
rocess to develop priority weights in manufacturing and packing
or speciﬁc Stock Keeping Units [68] . 
In summary, this leads to the following synthesising argument: 
Synthesising argument 3(b) : Generalisation models are meant
to identify and estimate explanatory or hierarchical relation-
ships between quantiﬁable attributes of a PSC from either past
evidence or subjective judgment. While the techniques used to
this purpose vary, their common aim is to overcome the need
for a detailed, mechanistic understanding of the PSC as a sys-
tem for modelling purposes. 
.3.3. Archetype III: outcome-based models 
A group of models referred to here as ‘Archetype III’ (18% of the
eviewed models) share an interpretation of the PSC as a collec-
ion of possible ‘states’ of the world as well as the consequences
ssociated to transitioning form one state to another. 
Central to most Archetype III models is the enumeration of
cenarios that could unfold as some uncertain variable reveals
tself over time, for example the outcome of a consecutive clinical
rials for new pharmaceutical products. The enumerated outcomes
re typically assessed based the possible sequences of occurrence,
nd some quantiﬁcation of resources needed in the case of a
peciﬁc realisation (see, for example, [69] ). 
In the vast majority of cases, Archetype III models are models
f a ‘pipeline’ in the development of new drug products, where
 variety of molecules compete for similar resources but differ
n terms of chances of commercialisation, and hence need to be
ccorded priority. However, this is not the only context in which
rchetype III arises. For example, some models with an emphasis
n drug preparation and administration scheduling were classiﬁed
s Archetype III, rather than Archetype I, due to their emphasis on
ransitioning between possible states (for example, patients visited
70] ) over what is supplied, how it is supplied, and to meet which
emand. Some models which embed elements of both Archetype
 and III were classiﬁed under the former for the opposite reason
such as [71] ). Example of how an Archetype III model enters the
ormulation of an Archetype I model include [72] and [71] . 
Similar to Archetype I models, the basic diagrammatic repre-
entation in Archetype III models consists of nodes and directed
82 E. Settanni et al. / Operations Research Perspectives 4 (2017) 74–95 
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n  arcs connecting those nodes. Typically, nodes are interpreted as
possible scenarios or states, and arcs as chronological rather than
technical precedence i.e., arcs do not represent some physical or
information ﬂow across nodes, rather, they represent the possibil-
ity of ‘moving’ from one node to the other as well as attributes
associated with such transition (e.g., probability of occurrence,
distance to be travelled etc.). Another similarity with Archetype I
models is that the presence or absence of a precedence relation-
ship between two nodes may be either given or determined as
part of the models solution procedure as in, for example, [73] . 
In summary, this leads to the following synthesising argument: 
Synthesising argument 3(c) : outcome-based models are often
used to represent stochastic relationships between states of the
world that occur stochastically as part of the research & devel-
opment pipelines and launch scenarios for new pharmaceutical
products, rather than relationships between the elements that
constitute the structure of a PSC. 
3.3.4. ‘Black-box’ algorithms and semi-quantitative models 
A residual category consists of those models where mathe-
matical notation is either insuﬃciently disclosed to classify the
model as one of the archetypes discussed in Sections 3.3.1 –3.3.4 ,
or the model is based on ‘hybrid’ approaches where elements of
conceptual and mathematical modelling coexist. About 20% of the
reviewed models fall into this residual category. 
Some ‘black-box’ approaches may actually disclose the un-
derpinning model of the supply chain via a lgorithms rather than
in mathematical terms, that is, using a sequence of instructions
framed according to certain syntax, as in a ﬂow chart or a
computer programming language. Examples include agent based
models (for example, [74] ) and other models where the emphasis
is placed on the results of a simulation and optimisation (for
example, [75] ). 
Hybrid models of the PSC, by contrast, typically are framed fol-
lowing the formalisms of system dynamics . These models typically
consist of a representation of the causal loops between opera-
tional variables that supposedly express the behaviour of the PSC,
and accompany such a representation with an indication of the
‘direction’ and nature of the relationships (for example [49,50] ).
While these models have, in principle, an underlying mathematical
counterpart [16] this was not disclosed in the reviewed works. 
3.4. Economic aspects in PSC models 
The main economic aspects of the PSC, captured by the re-
viewed models, are cost, revenues and demands. The structure
of payments being a distinguishing feature of the relationship
between a PSC and the healthcare system of a speciﬁc country,
this structure is typically captured in conceptual models such as
[76,77] , rather than in mathematical models of the PSC. 
Cost is a prominent economic aspect in Archetypes I and
III. Although with a varying level of granularity across all the
reviewed models, cost is attributed to products by direct costing,
where the direct product costs involved may be ﬁxed or variable
with respect to product volumes (see, for example, [78] ). More
sophisticated costing approaches such as Activity Base Costing
and Cost of Quality are rarely applied in a PSC context, and are
typically disconnected from the formulation of engineering PSC
models (for example [79,80] ). 
Generally, unit values for ‘cost’ and ‘revenues’ are known model
parameters that are meant to be multiplied with some level of
activity once determined by solving a speciﬁc PSC model (for
example the amount of material or batches produced in a facility;
or the capacity level after investment in additional facilities). Al-
though some works frame production costs as functions, these areypically ﬁxed upfront as in, for example, [53] . Costs and revenues
hus determined are then combined in a ﬁgure of merit—typically
n the form of proﬁt or net present value—to be optimised to
ventually determine some ‘optimal’ conﬁguration and level of
peration of the PSC. 
With regards to Archetype I models, the most occurring unit
onetary worth parameters include: inventory holding (75%);
anufacturing (57%); ﬁnal drug product (54%); penalties and op-
ortunity costs (39%); transportation and distribution (32%); prod-
ct scrapping (25%); setups and clean-ups in batch manufacturing
22%); investment in new or expanded capacity (22%); purchase
rders placement (18%); raw materials (14%); taxes and import du-
ies (11%); quality control (11%). Only a few works consider other
ost items such as packaging costs, R&D costs, marketing and sales
osts, labour cost and equipment depreciation. Conversely, the
ain example of economic PSC aspects in Archetype II is the use
f data points expressed in monetary units. For example, the main
ataset used in [64] consists of monthly sales and advertising
xpenditures. For archetype III, it is common to refer to ‘resources’
mployed in the new product pipeline (e.g., testing facilities), and
o assign a given monetary worth which is assumedly known
pfront. Assumptions that link revenue to the time a new product
s introduced to market are also common, for example [69] . 
Demand is an aspect mainly related to Archetype I models. In
he absence of end-to-end visibility through real-time collection
nd communication of biometric patient data, the demand of drug
roducts is typically considered to be exogenous element and fore-
asted rather than managed. Seldom is a detailed demand forecast
sing patient-based or prescription-based approaches [81] incor-
orated in a PSC model. In 22% of cases, demand is stochastically
enerated—for example, the demand over lead in the case of
linical trial inventory modelling [42] —and in 75% of cases it is a
iven, as in production scheduling problems [58] , or expressed in
ome functional form speciﬁed upfront—such as linking demand
ith market price elasticity [82] . Among the few exceptions,
ansen and Grunow [51] use insights from case study research to
ormulate stochastic demand generation for a new drug product. 
In summary, while economic aspects are crucial to model the
onﬁguration and behaviour of a PSC the determination of such
spects is not at the heart of the PSC modelling intent. In most
ases, economic aspects are parameters assumed to be known or
asily knowable, and economic evaluations across the PSC almost
xclusively consist of a direct costing exercise. 
.5. Solution approaches and implementation 
The evaluation grid in Fig. 1 includes activities in solving
athematical models formulated, and also takes into account
he actions in implementing the solution thus determined in real
orld settings. As outlined in Section 2 , most existing reviews
lace the focus on how mathematical models of the supply chain,
n general, and the PSC in particular are solved. 
Circa 14% of the reviewed references did not specify how the
athematical model presented was solved. Explicitly mentioned
olution methods include algebra (5%), optimisation algorithms
42%) although in most cases the insights provided is limited to a
eference to the off-the-shelf solver employed (exceptions include,
or example, [59] ); numerical methods such as simulation (5%);
nd undisclosed algorithmic approaches (28%) including artiﬁcial
ntelligence methods; and heuristics (7%). 
For most reviewed papers do not report on whether the mod-
ls outlined were implemented in real-world settings, and what
ere the implications. Among the few exceptions, [55] explicitly
rovides an application to solid dosage manufacturing in India,
one of the reviewed references speciﬁes whether any action
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models are implemented. as taken by businesses based on the solution obtained for the
roposed PSC model. 
. Discussion 
In this paper, a selection of extant models was evaluated in
erms of their ability to enhance the analyst’s understanding of
he inherent characteristics of a PSC as the system of interest. A
ystems view of OR enabled the identiﬁcation of some archetypal
spects of PSC modelling throughout the typical activities under-
aken by the analyst, from the identiﬁcation and conceptualisation
f the relevant system, through the formulation and solution of
athematical models, to the implementation of the obtained
olution to inform managerial practices. These ﬁndings, as well as
he possible implications for theory and practice in the light of
he challenges currently faced by the pharmaceutical industry are
ummarised in Table 3 , and discussed below. 
.1. System identiﬁcation 
As outlined in the introduction, traditional pharmaceutical
anufacturing is now facing challenges associated with the need
or more patient-centric supply chains capable of delivering
reater drug product personalisation; in supporting more partic-
pative healthcare through digital medical devices; and leveraging
dvances in novel continuous processing to enable more dispersed
nd responsive manufacturing models. Higher-level narratives tend
o emphasise the intrinsic merits of single interventions aimed
t attaining improved healthcare outcomes through, for example,
nnovative manufacturing technologies. Rigorous analytical frame-
orks to capture PSC reconﬁguration opportunities from a ‘truly’
nd-to-end/whole-system perspective have been proposed [7] , but
perate mostly at the conceptual level. 
Seldom does a deﬁnition of PSC adequately highlight other
istinctive features of the underpinning phenomenon than the
nal product delivered. Most deﬁnitions fail to address the ‘sys-
em’ qualiﬁcation of a PSC, and to frame its aims with the patient
nd the treated condition in mind. In some cases, it is diﬃcult
o distinguish between the purpose of a PSC and the constraints
mposed on how such a purpose should be achieved, for example
cost effectively”, or “with minimum environmental impact”.
nsights into a possible deﬁnition of PSC are offered in Section
 (research ﬁndings). An explicit reference to the notion of sys-
em is suﬃcient to address the presence of multiple, purposeful
lements in a PSC and the linkages between them. The social
nd technical nature of such elements characterises the general
oncept of supply chain [38] , but the intended ﬁnal delivery
hould be distinctive of a PSC. 
The term ‘network’ is often used along with ‘system’ to enrich
he concept of PSC, and sometimes it pinpoints the fact that a ﬁrm
ay be simultaneously part of multiple supply chains [83] . More
ften its meaning is simply left to interpretation. In line with
revious research [12,38] , the concept of network should be used
o describe speciﬁc architectural structures that may be observed
n a system, and to direct the attention towards a speciﬁc analytic
ens to evaluate such structures. 
To enable further research, for example through testable propo-
itions, a speciﬁc deﬁnition of PSC should be evaluated according
o the rules of formal conceptual deﬁnition outlined by Wacker
84] . For illustrative purposes, such rules are applied to compare
he PSC characterisation suggested in Section 3.1 with a selection
f generic deﬁnitions of supply chain, as shown in Appendix B . 
The above leads to the following implications: 
• From a theoretical perspective, the point of focus of PSC models
should shift from the volumes of individual pharmaceuticalproducts moved across the supply network, to the healthcare
outcomes these volumes contribute to attain (or not). This
could be achieved by introducing the concept of “functional
unit”, which is well-established in modelling end-to-end envi-
ronmental aspects, to formalise a pharmaceutical product “in
use”. 
• From a practical perspective, it is key to realise that, while cur-
rent models of the PSC may help with “polish the factory”, the
beneﬁts of local optimisation could be offset by the dynamics
of complex distribution and healthcare delivery systems, as well
as patient behaviour in the downstream segment of the PSC.
Currently, these aspects are treated as a ‘black box’ in PSC mod-
elling, and addressed aggregately through demand forecasts. 
.2. System representation 
In principle, it is desirable to simultaneously develop a pic-
orial representation and a mathematical model of the system
nder study to ensure that the interrelationships within such a
ystem are appropriately captured [16] . Despite the seminal work
f Sagasti and Mitroff [15] conceptual and mathematical mod-
lling continues to be the province of specialist approaches—e.g.,
upply chain mapping though case study research, and supply
hain design and optimisation—and hence tend to be developed
n isolation, and are not meant to complement each other. For
xample, works such as Watson et al. [22] recognise the value of
sing supply chain maps to achieve a common understanding of
he problem situation within inter-disciplinary teams involved in
 network design project. However, the topic appears to be subor-
inate to, and is approached with less methodological rigour than
he mathematical aspects of modelling. With speciﬁc reference
o PSC, seldom is a structured approach to supply chain mapping
mployed. Rather, diagrammatic representations, if any, are un-
tructured and decoupled from the computational aspects of a PSC
odel (for example, [85,86] ). In other cases, a pictorial represen-
ation is used for the sole purpose of illustrating the variables in
 mathematical model of a PSC (for example, [42,69] ). Exceptions
uch as [51] explicitly link the formulation of a mathematical
odel of the PSC for use in planning new products market launch,
uilding on evidence from qualitative data gathered through case
tudy research. Although only conceptually, Srai et al. [7] outline
n approach to network design and systems integration where
ndustrial systems analysis and supply chain mapping techniques
oexist with, and complement, an analytical evaluation of current
nd future states of a pharmaceutical supply network. 
The above leads to the following implications: 
• From a theoretical perspective, mapping the current state of
a PSC, as well as the re-conﬁguration opportunities arising
from speciﬁc technology interventions should be regarded as
a necessary premise to the formulation of meaningful and de-
fensible mathematical models of the PSC. This requires a shift
from regarding PSC mapping as a “nice to have” in addition to
mathematical modelling, to considering it as an integral part of
the systems view of OR, to be approached with methodological
rigour and supported by evidence. 
• From a practical perspective, mapping current and future PSC
conﬁgurations is necessary to establish realistic boundaries
conditions (breadth) and scope (depth) when exploring the
relative attractiveness of potentially disrupting technology 
interventions e.g., in medicine manufacturing or healthcare
management from an OM&SC perspective, thus ensuring con-
sistency and “like for like” comparisons when mathematical
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Table 3 
Summary of ﬁndings and gap identiﬁcation. 
Modelling phase (Research 
question) 
Proposed conceptualisation Synthesising argument based on literature Gaps and recommendation 
System identiﬁcation: (What is 
meant by PSC?) 
The PSC is a socio-technical system aimed 
to align ﬁrms in enabling the 
achievement of improved health status 
through medicines provision. 
Complementary and alternative 
products and process technologies may 
coexist within such a system 
The PSC is mostly identiﬁed as a 
product-centric, linear sequence of 
stages which spans across the 
manufacture and physical distribution 
of medicines 
Currently, a rigorous ‘system’ qualiﬁcation of the PSC and a patient-centricity perspective is lacking. 
While current models of the PSC may help with “polish the factory”, the beneﬁts of local 
optimisation could be offset by the dynamics of complex distribution and healthcare delivery 
systems, as well as patient behaviour in the downstream segment of the PSC. Future models 
should therefore address which healthcare outcomes the PSC must contribute to attain for 
pharmaceutical products to deliver value “in use”. Greater compliance with theory of formal 
conceptual deﬁnition should be sought to generate propositions concerning the PSC that can be 
appropriately tested and therefore facilitate further research. 
System representation (Which 
phenomenon is represented in 
a model of the PSC?) 
The identiﬁcation and representation of 
the system of interest is an explicit and 
formalised activity aimed to delimit the 
areas of concern for the analyst by 
deﬁning the scope and boundaries for 
the problem situation. 
Most conceptual models of the PSC 
consist of loosely formalised 
diagrammatic representations of 
heterogeneous objects of analysis, such 
as whole organisations; distribution 
topologies; digital infrastructures; 
multi-facility production systems, or 
workﬂows within individual facilities. 
Occasionally, such diagrammatic 
representations are underpinned by 
qualitative data analysis. 
With rare exceptions, qualitative and quantitative models are developed through ‘silos’ approaches. 
Most mathematical models of the PSC are decoupled from a rigorous conceptualisation and 
representation of the problem situation, namely the current and future state of the system of 
interest. A shift is required from regarding PSC mapping as a “nice to have” in addition to 
mathematical modelling, to considering it as an integral part of the systems view of OR, to be 
approached with methodological rigour and supported by evidence The practical beneﬁts of such 
shift is the ability to establish realistic boundaries conditions (breadth) and scope (depth) when 
exploring the relative attractiveness of potentially disrupting technology interventions in terms of 
PSC reconﬁguration. 
System quantiﬁcation (How is the 
modelled PSC quantiﬁed?) 
A mathematical model of the PSC enables 
the analytical evaluation of the current 
and future states of multi-tier supply 
networks trough quantiﬁable metrics 
that adequately reﬂect its structural and 
behavioural characteristics in 
responding to changes in market 
demands and patient needs while 
ensuring an end-to-end eﬃcient use of 
resources 
Archetype I models represent the 
behaviour of a PSC as a mechanism to 
align supply and demand of medicines 
and related materials across a 
multi-echelon production-inventory 
system, where the structure of such a 
system is deﬁned in terms of technical 
and temporal dependencies. Typically, 
the patient’s condition is outside the 
boundaries of a PSC, and the technology 
interventions in manufacturing and 
information management remain 
implicit. 
Within Archetype I, models of the PSC tend to specialise in representing silos of activity such as 
manufacturing, inventory management, and distribution: An end-to-end, customers-centric 
perspective is therefore absent thus making it diﬃcult to make a reliable business case to evaluate 
opportunities arising from technology interventions. To enable future research an archetype I PSC 
model should clearly address the following elements: 
• Functional unit, ideally capturing one or more pharmaceutical products “in use”; 
• Boundaries and scope, specifying which variables are exogenous (for example, demand), which 
elements of the delivery system are included; and what are the relationships between such 
elements in terms of technological and temporal dependency 
• Underpinning technological knowledge; 
• Assumptions about sources and nature of underpinning data (for example, real-time data streams 
versus “one off” data snapshots) 
Archetype II models are meant to identify 
and estimate explanatory or 
hierarchical relationships between 
quantiﬁable attributes of a PSC from 
either past evidence or subjective 
judgment. While the techniques used to 
this purpose vary, their common aim is 
to overcome the need for a detailed, 
mechanistic understanding of the PSC 
as a system for modelling purposes . 
Archetype II models are data-driven in the sense that presuppose the existence of empirical evidence 
in the form of a data pool. Insofar as adequate data is available, these models can be useful to 
explore explanatory relationships between speciﬁc, quantiﬁable attributes of a PSC. To enable 
future research Archetype II models should prioritise replicability by greater transparency of the 
following: 
Data sets (retrospective observations; elicited subjective opinion) and modes of collection Inference 
and ranking mechanisms 
• Exploration of the underpinning data given the nature of the represented variable (for example 
categorical as in scores, or continuous) 
• Suitability of the underpinning method of analysis (for example parametric, or non-parametric) to 
the nature of the modelled phenomena 
• Reliability, validity and ‘goodness of ﬁt’ considerations 
Archetype III models are often used to 
represent stochastic relationships 
between ‘states of the world’ that occur 
stochastically as part of the research & 
development pipelines and launch 
scenarios for new pharmaceutical 
products, rather than relationships 
between the elements that constitute 
the structure of a PSC 
Little or no detail is provided on how the probabilities of transitioning between states of the world 
in Archetype III models come about (for example, as a result of analysing a historical track record 
of empirical evidence or by eliciting knowledge from experts). A clearer link with the empirical 
evidence underpinning these models is therefore required. Linked to this aspect is the need to 
address the theoretical nature of quantifying probabilities, leading to whether a Bayesian or a 
frequentist approach is more suitable. Also, it may be worth exploring similarities and differences 
between Archetype III models used upstream in the PSC, for example to model product portfolio 
pipeline, and those used downstream to model the arising complications for patients conditions 
such as diabetes 
E. Settanni et al. / Operations Research Perspectives 4 (2017) 74–95 85 
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In the quest for the “best” supply chain conﬁguration design,
eldom are the merits of engaging in some kind of optimisation
xercise questioned. PSC models are simply expected to become
ncreasingly sophisticated, and to deliver exact numerical solu-
ions to problems involving competing social, environmental and
conomic objectives, and a prohibitively large number of variables
31] . A common oversight is that a mathematical model of an
ndustrial system is useful insofar as it aids in understanding that
ystem—with no implication that the results need to be perfect
16] . By developing strong anchoring points in the way a problem
s framed and structured through a model operation researchers
ay put at risk their ability to observe, understand and manage
he system created by the modelling process [87] . 
Although with a focus on survey research in SC&OM, Melnyk
t al. [88] emphasise the importance of full disclosure of the
echniques used in the extant literature, and explicitly identify a
inimum amount of information that should be disclosed by the
nalyst to improve the accumulation of knowledge through the ap-
lication of such techniques. In a similar fashion, the key elements
o assess the quality of each PSC modelling archetype identiﬁed in
ection 3 are summarised in Table 3 , along with recommendations
n how to overcome some of the current speciﬁc limitations. 
From a real-world application perspective, as pharmaceutical
roducts become more complex, individualised and on-demand,
ew production technologies such as continuous manufacturing,
rocess analytical technologies, and nano-structured drug de-
ivery systems processing are needed to augment the classical
anufacturing routes [89] . However, the ﬁndings of this research
uggests that an understanding the underpinning manufacturing
nd information technologies, aggregately referred here with the
erm technological knowledge, currently play a limited role in the
ormulation of PSC models. While this appears in line with the
oint that in the pharmaceutical industry, plant design tends to be
ery traditional, with no real change in manufacturing technology
or 50 years [90] , it seems legitimate to wonder how can the ana-
ytical tools developed in such a context can support an evaluation
f emerging reconﬁguration opportunities arising from medicine
anufacturing and more patient-centric business models. Most
odels of the PSC are developed with production planning and
cheduling in mind, rather than in comparing the merits of al-
ernative product or process technologies or business models.
lthough with reference to environmental aspects only, PSC mod-
ls have been developed with a Life Cycle Assessment approach
hat are inherently comparative in nature (for example, [91] ). 
Information ﬂows and the use of digital technologies is also
n emerging topic, which plays a limited role in the formulation
f current PSC models. With the exception of Archetype II mod-
ls, which are inherently data-driven, most PSC models do not
rovide insight into how the data, which supposedly are needed
o populate them, are to be generated, stored, retrieved and
ransmitted. Models, by contrast, entirely devote themselves to
nformation technology solutions such as, drug anti-counterfeiting
47] , Vendor Managed Inventories [46] , and hospital inventory
anagement [45] and conﬁne themselves to the design of the
igital infrastructure necessary to the purpose at hand. Less
tructured representations are also used to model conceptually
atient-centric digital homecare solution [48,63] . 
Economic considerations are present in 90% of the reviewed
eferences, typically in terms of product-related ‘cost’ and ‘rev-
nues’. However, the economic aspects become apparent only
hen the PSC is embedded in a ‘broader’ modelling exercise. In
0% of the cases, economic values such as ‘cost’ are assumed to
e common knowledge data rather than metrics that need to be
etermined through a modelling effort. Although without speciﬁceference to the PSC, concepts such as Total Cost of Ownership
92] , and Supply Chain Costing [93] have long addressed the
omplexities related to estimating and managing costs beyond the
oundaries of the individual ﬁrm to better exploit downstream
nd upstream linkages, reﬂecting the nature of the relationships
etween supply chain partners. Conversely, in the reviewed ref-
rences cost modelling is treated as a separate problem from
etermining how the ‘optimal’ conﬁguration of the PSC will look
ike. Activities such as cost attribution to products or cost estima-
ion typically remain in the background as they are assumed to
e preliminarily carried out. In the absence of additional insight
n how these costs are derived, whether and to what extent the
valuation of cost may be recursively affected by the PSC model it
ontributes to optimise remain unclear. 
Another economic aspect is demand estimation and modelling.
ith reference to healthcare systems the importance of detecting
hanges in demand patterns to ensure more responsive delivery
as been presented [81,94] . However, the ﬁndings suggest that
n framing a PSC model knowledge of demand is assumed to
e available, either as a deterministic datum or as a stochastic
unction capable of generating it. 
Finally, an emerging theme that is largely undetected in the
xamined literature is the ‘end-of-life’ stage within PSC. As phar-
aceuticals products become more largely utilised, the routes of
ontamination through the food chain, and the challenges posed
y new compounds to the treatment of wastewater become of
reater concern (for example, [95] ) and can only be detected by
aking a ‘circular’ view on an economy. Only one of the retrieved
eferences addresses medicines end-of-life aspects [96] . However,
or its specialist approach and object of analysis it was deemed
utside scope. 
This leads to the following implications: 
• From a theoretical perspective, the agnosticism of mathemati-
cal PSC models towards the characteristics of the underpinning
manufacturing, service provision and information technologies 
characterising alternative PSC conﬁgurations will need to be ad-
dressed to ensure that the merits of alternative product or pro-
cess technologies or business models are adequately compared.
• From a practical perspective, future PSC models should bridge
the gap between modelling medicine manufacturing and distri-
bution operations, and modelling the usage of pharmaceutical
products downstream through healthcare service provision
workﬂows. 
. Conclusions 
The research presented in this paper was motivated by the
ebate on how best to evaluate the multifaceted aspects of PSC
econﬁgurations opportunities enabled by technology interven-
ions in medicine manufacturing, as well as more patient-centric
elivery models. To do so, a critical synthesis of the approaches
ommonly employed in the academic literature and industry
ractice was presented—to identify the relevant engineering–
conomic aspects of a PSC; to conceptualise those aspects through
isualisation, and to evaluate them analytically. Synthesising argu-
ents were obtained to address the following questions: “What
s meant by PSC for modelling purposes?”; and “How is a PSC
onceptualised through visualisation?”; “Which aspects of a PSC
re expressed quantitatively, and how”? 
The main contribution of this research is the application of
 systems approach to OR problems, expanding on the seminal
ork of [15] , to critically evaluate gaps between the characteristics
f a PSC, which are currently modelled, and those that should
e considered in a context where reconﬁgurations opportunities
re being targeted. In the absence of a systems view of OR,
86 E. Settanni et al. / Operations Research Perspectives 4 (2017) 74–95 
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Aexisting work tends to focus on the effectiveness and eﬃcacy of
model-solving activities, while overlooking potentially relevant
aspects such as conceptual modelling, how a conceptual model
informs the outline of a mathematical model, and which actions
are eventually informed by the identiﬁed solution. 
While application of critical interpretative synthesis is not new,
to the authors’ knowledge this is one of the ﬁrst attempts to apply
it to textual data expressed in mathematical rather than natural
language. This application resulted in a major departure from
existing reviews that enumerate and classify models based solely
on the approach declared in the reviewed reference. Finally, this
research distinguishes between models that refer to broader man-
agerial problems concerning a PSC (for example, rank alternatives,
or optimise a ﬁgure of merit), and models of the PSC itself, with
a particular emphasis on its ‘system’ qualiﬁcation. This distinction
is in line with a shift in theory building, from emphasising supply
chain management , to emphasising what is purportedly managed. 
Most concepts and models of the PSC are misaligned with
the view that a more patient-centric delivery solutions should
be pursued. In principle, the most advocated position is that
the PSC should be embedded in its broader ecosystem—namely,
healthcare provision—most models draw their boundaries up to a
point where a physical product reaches the shelves, regardless of
whether and how effectively it is used to treat a condition. Based
on the reviewed items, neither the deﬁnitions nor the models of
the PSC available seem to reﬂect the theoretical view that more
patient-centric delivery solution should be pursued. 
While it is recognised that end-to-end beneﬁts of future PSC re-
quire assessment of speciﬁc technology intervention, most models
disclose little or no insight into the underpinning manufacturing
technology being evaluated. This also applies to information and
communication technologies, as most models do not provide
insight into how the data which supposedly are needed to popu-
late them are to be generated, stored, retrieved and transmitted.
Finally, while operations research plays a prominent role in the
formulation and solution of most PSC models, the achievement
of a preliminarily understanding of the PSC through formalised
supply chain mapping is either absent or poorly structured. Economic aspects profoundly determine how an ‘optimal’ PSC
onﬁguration may look like. However, these aspects are largely
reated as common knowledge rather than modelled in turn in
uch a way as to investigate whether, and to what extent, the
valuation of cost may be recursively affected by the PSC model it
ontributes to optimise. 
This research has a series of limitations. Conclusions are drawn
rom a limited sample of the literature on the topic. Alternative
ombinations of search strategies and librarian resources may have
ed to a different sample. In addition, despite the authors’ effort s to
uarantee methodological rigour, an inherent element of subjectiv-
ty in shaping the synthesising argument could not be eliminated. 
Currently, the quality of a model of the PSC in particular, and of
 supply chain in general, seem to reside in its degree of sophisti-
ation and obscurity to the user. Achieving ambitious results such
s reconciling conﬂicting environmental and economic objectives
nd making accurate predictions about the future appears more
ppealing than contributing to our understanding of a problem
ituation. Future research is needed to help inform the analyst’s
nderstanding of how value is delivered in use to the patient to
ttain beneﬁcial outcomes, rather than chasing ‘precision’ while
eaving the most relevant part of the problem outside the scope
nd boundaries of the analysis. From a methodological perspective,
here are ample margins to develop better interfaces between con-
eptual and mathematical modelling, linking more systematically
upply chain visualisation and mapping techniques to the identiﬁ-
ation and formulation of appropriate supply chain analytics. From
 practical perspective, academics and practitioners should be able
o navigate a growing, intricate landscape of approaches to PSC
odelling with a more critical eye, rather than having to commit
o speciﬁc tools and techniques a priori. 
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Table A.1 
Reviewed primary literature, system-related dimensions. 
Reference Context Modelled phenomenon Diagram Boundaries Scope Relationships 
COM NPD PIS PRS IDS ITI PDP PBI NNA CEF PSE SIS SUN ECS SCE SIT RES ACT CAM PMT PMA MSC DST INF TPR ETR 
[102] Excluded (saturation) 
[82] ● ● ● ● ● ● ● ●
[63] ● ● ● ● ● ● ●
[103] ● ● ● ● ● ●
[104] ● ● ● ● ● ●
[70] ● ● ● ● ● ● ●
[62] ● ● ● ● ● ● ● ● ● ● ● ●
[105] Excluded (saturation) 
[96] Excluded (out of scope) 
[68] ● ● ● ● ●
[69] ● ● ● ● ● ● ●
[45] ● ● ● ● ● ● ●
[46] ● ● ● ● ●
[79] ● ● ● ● ● ●
[55] ● ● ● ● ● ● ● ●
[66] ● ● ● ● ● ●
[106] ● ● ● ● ● ●
[42] ● ● ● ● ● ●
[71] ● ● ● ● ● ● ● ● ● ● ●
[49] ● ● ● ● ● ●
[107] ● ● ● ● ● ● ● ●
[108] ● ● ● ● ● ● ●
[51] ● ● ● ● ● ● ● ● ● ●
[74] ● ● ● ● ● ● ●
[109] ● ● ● ● ● ● ●
[64] ● ● ● ● ● ●
[67] ● ● ● ● ● ●
[59] ● ● ● ● ●
[110] ● ● ● ● ● ● ● ● ● ● ●
[111] ● ● ● ●
[75] ● ● ● ● ● ●
[60] ● ● ● ● ●
[112] ● ● ● ● ●
[72] ● ● ● ● ● ● ● ● ● ● ● ●
[113] Excluded (saturation) 
[11] Excluded (out of scope) 
[58] ● ● ● ● ● ● ● ● ●
[53] ● ● ● ● ● ●
( continued on next page ) 
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Table A.1 ( continued ) 
Reference Context Modelled phenomenon Diagram Boundaries Scope Relationships 
COM NPD PIS PRS IDS ITI PDP PBI NNA CEF PSE SIS SUN ECS SCE SIT RES ACT CAM PMT PMA MSC DST INF TPR ETR 
[114] Excluded (saturation) 
[78] ● ● ● ● ● ● ● ● ● ●
[50] ● ● ● ● ● ●
[115] Excluded (saturation) 
[76] ● ● ● ● ● ● ●
[116] ● ● ● ● ● ● ●
[117] ● ● ● ● ● ● ● ● ●
[57] ● ● ● ● ● ● ● ●
[37] Excluded (out of scope) 
[118] ● ● ● ● ● ● ● ● ●
[47] ● ● ● ● ● ●
[73] ● ● ● ● ● ● ●
[91] ● ● ● ● ● ● ● ●
[65] ● ● ● ● ● ● ● ●
[85] ● ● ● ● ● ● ● ● ●
[80] ● ● ● ● ●
[119] ● ● ● ● ● ● ● ● ●
[120] ● ● ● ● ● ● ● ●
[121] Excluded (saturation) 
[61] ● ● ● ● ● ● ● ● ● ● ●
[122] ● ● ● ● ● ● ● ● ● ●
[123] ● ● ● ● ● ● ●
[77] ● ● ● ● ● ● ●
[39] ● ● ● ● ● ● ●
[124] ● ● ● ● ● ●
[86] ● ● ● ● ● ● ●
[48] Excluded (out of scope) 
[125] ● ● ● ● ● ● ●
[126] ● ● ● ● ● ● ●
COMM: Commercial Supply Chain (existing product); CLI/ NPD: Clinical Trial Supply Chain / New Product Development; PIS: Production-Inventory System; PRS: Production System; IDS: Inventory and Distribution System; 
ITI: Information Technology Infrastructure; PDP: Product development pipeline; PBI: Practice/Behaviour in Industry; NNA: non-formalised node-arc diagram; CEF: Cause/Effect (such as, causal loops; failure modes and 
effect); PSE: Process system engineering (such as recipe diagrams, State-Task-Network); SIS: Single site; SUN: Supply Network; ECS: Economy sector; SCE: Scenario; SIT: Site/Location, or organisation; RES: Resources (such as 
Equipment/Machinery, Production line, personnel); ACT: Activity/Task; CAM: Campaign; PMT: Products/Materials, by type; PMA: Product/Materials, by age; MSC: Materials supplier-customer; DST: distance; INF: Information 
Flows; TPR: Temporal precedence / cause-effect; ETR: Economic transactions. 
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Table A.2 
Reviewed primary literature, manufacturing dimensions. 
Reference Geography Product life-cycle stages Pharmaceutical product technology Manufacturing technology Real-word implemented 
PDV STM PRM SEM PCK TRN DIST USE WST SDF LDF INJ ONC VAC BAT CNT DIG 
[102] Excluded (saturation) 
[82] EU ● ● ● ● ●
[63] n.s. ● ● ● ● ● ●
[103] EU ●
[104] n.s. ●
[70] n.s. ● ● ● ●
[62] US, EU ● ● ● ● ● ● ●
[105] Excluded (saturation) 
[96] Excluded (out of scope) 
[68] India ● ●
[69] n.s. ●
[45] EU ●
[46] EU ●
[79] n.s. 
[55] India ● ● ● ● ● ●
[66] EU ● ● ● ●
[106] n.s. ● ● ●
[42] US, EU, RU ● ● ●
[71] n.s. ● ● ●
[49] n.s. ●
[107] n.s. ● ●
[108] US ● ● ● ● ●
[51] n.s. ● ● ● ● ●
[74] n.s. ● ● ● ●
[109] EU ●
[64] India ●
[67] n.s. ● ● ● ●
[59] n.s. ●
[110] n.s. ● ● ●
[111] n.s. ●
[75] EU ● ●
[60] n.s. ● ● ●
[112] n.s. ●
[72] n.s. ● ●
[113] Excluded (saturation) 
[11] Excluded (out of scope) 
[58] n.s. ● ● ●
[53] US, Asia ●
( continued on next page ) 
9
0
 
E
.
 Setta
n
n
i
 et
 a
l.
 /
 O
p
era
tio
n
s
 R
esea
rch
 P
ersp
ectives
 4
 (2
0
17
)
 7
4
–
9
5
 
Table A.2 ( continued ) 
Reference Geography Product life-cycle stages Pharmaceutical product technology Manufacturing technology Real-word implemented 
PDV STM PRM SEM PCK TRN DIST USE WST SDF LDF INJ ONC VAC BAT CNT DIG 
[114] Excluded (saturation) 
[78] n.s. ● ● ● ● ● ●
[50] India ● ●
[115] Excluded (saturation) 
[76] US ●
[116] n.s. ●
[117] n.s. ● ●
[57] n.s. ● ● ●
[37] Excluded (out of scope) 
[118] n.s. ● ●
[47] n.s. ● ●
[73] n.s. ●
[91] EU ● ● ● ● ●
[65] EU ●
[85] n.s. ● ● ●
[80] India, EU ● ● ●
[119] EU ● ● ●
[120] n.s. ●
[121] Excluded (saturation) 
[61] n.s. ● ● ●
[122] n.s. ● ● ● ● ● ●
[123] US ●
[77] US ●
[39] n.s. ●
[124] UK ● ●
[86] Africa ● ●
[48] Excluded (out of scope) 
[125] n.s. ●
[126] China ● ●
PDV: Product development; STM: Starting materials manufacture; PRM: Primary manufacturing (Active pharmaceutical ingredients); SEM: Secondary manufacturing (dosage forms); PCK: Product packaging; TRD: Transport; 
DST: distribution (wholesale/dispensing pharmacies); USE: medicine utilisation; WST: waste medicine disposal; NS: not speciﬁed; SDF: Solid dosage form; LDF: Liquid dosage form; INJ: Injection; ONC: Oncology; VAC: 
Vaccines; BAT: Batch; CNT: Continuous; DIG: Digital information technologies. 
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Table A.3 
Reviewed primary literature, mathematical modelling dimensions. 
Reference Mathematical model Solution 
Classiﬁcation Matrices (deﬁnitions in Fig. 2 and Table 2 ) Tech depend formal Temp depend formal Approach to 
Uncertainty 
COP SIM AHC ALG SUJ 
V V_e U U_p U_c U_e s d b f tau FXT CBR None INT LAG None DET PRB 
[102] Excluded (saturation) 
[82] Archetype I ● ● ● ● ● ● ● ● ● ● ● ● ●
[63] Archetype I ● ● ● ● ● ● ● ● ●
[103] Archetype I ● ● ● ● ● ● ● ● ● ●
[104] Archetype III ● ● ● ● ●
[70] Archetype III ● ● ● ●
[62] Archetype I ● ● ● ● ● ● ● ● ● ●
[105] Excluded (saturation) 
[96] Excluded (out of scope) 
[68] Archetype II ● ● ● ● ●
[69] Archetype III ● ● ● ● ●
[45] Archetype II ● ● ● ●
[46] N/A 
[79] N/A 
[55] Archetype I ● ● ● ● ● ● ● ● ● ● ● ● ● ●
[66] Archetype II ● ● ● ● ● ● ●
[106] Archetype I ● ● ● ● ● ● ● ● ● ●
[42] Archetype I ● ● ● ● ● ● ● ●
[71] Archetype I ● ● ● ● ● ● ● ● ● ● ● ● ●
[49] Hybrid/BB ●
[107] Archetype I ● ● ● ● ● ● ● ● ● ●
[108] Archetype I ● ● ● ● ● ● ● ● ● ● ● ●
[51] Archetype I ● ● ● ● ● ● ● ● ● ● ● ● ●
[74] Hybrid/BB ● ●
[109] Archetype I ● ● ● ● ● ● ● ●
[64] Archetype II ● ● ● ●
[67] Archetype II ●
[59] Archetype I ● ● ● ● ● ● ● ● ● ● ●
[110] Archetype I ● ● ● ● ● ● ● ● ● ● ● ● ●
[111] Archetype II ● ● ●
[75] Hybrid/BB ● ● ● ●
[60] Archetype III ● ● ● ● ● ● ● ●
[112] Archetype III ● ● ● ● ●
[72] Archetype III ● ● ● ● ● ● ● ● ● ● ●
[113] Excluded (saturation) 
[11] Excluded (out of scope) 
[58] Archetype I ● ● ● ● ● ● ● ● ●
[53] Archetype I ● ● ● ● ● ●
( continued on next page ) 
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Table A.3 ( continued ) 
Reference Mathematical model Solution 
Classiﬁcation Matrices (deﬁnitions in Fig. 2 and Table 2 ) Tech depend formal Temp depend formal Approach to 
Uncertainty 
COP SIM AHC ALG SUJ 
V V_e U U_p U_c U_e s d b f tau FXT CBR None INT LAG None DET PRB 
[114] Excluded (saturation) 
[78] Archetype I ● ● ● ● ● ● ● ● ● ● ● ●
[50] Hybrid/BB ● ●
[115] Excluded (out of scope) 
[76] N/A 
[116] Hybrid/BB ● ● ●
[117] Hybrid/BB ● ●
[57] Archetype I ● ● ● ● ● ● ● ● ● ● ●
[37] Excluded (out of scope) 
[118] Archetype I ● ● ● ● ● ● ● ● ● ● ● ● ●
[47] N/A 
[73] Archetype III ● ● ● ● ●
[91] Hybrid/BB ● ● ● ●
[65] Archetype II ● ● ●
[85] Archetype I ● ● ● ● ● ● ● ● ● ● ●
[80] Archetype II ● ● ● ●
[119] Hybrid/BB ● ● ● ● ●
[120] Archetype III ● ● ● ● ● ● ●
[121] Excluded (out of scope) 
[61] Archetype III ● ● ● ● ● ● ● ● ● ●
[122] Archetype I ● ● ● ● ● ● ● ● ● ● ● ●
[123] Archetype I ● ● ● ● ● ●
[77] N/A 
[39] Archetype I ● ● ● ● ● ● ●
[124] N/A 
[86] Archetype II ● ● ●
[48] Excluded (out of scope) 
[125] Archetype I ● ● ● ● ● ● ●
[126] Archetype I ● ● ●
N/A: not applicable (e.g., conceptual or case study); FXT: Fixed topology; CBR: Cookbook recipe/technical coeﬃcient given; INT: Inter-temporal (consecutive time slices); LAG: time-lagged (non-consecutive time slices); DET: 
Deterministic; PRB: Probabilistic; COP: Constrained optimisation (include data envelopment analysis, and curve-ﬁtting e.g., least squares); SIM: Simulation; AHC: Artiﬁcial intelligence/Heuristics/Classiﬁcation algorithm; ALG: 
Algebraic, closed form; SUJ: Subjective judgment e.g., scoring system. 
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upply chain, and generic supply chain according to the rules of formal 
c
iding 
“and, 
d by 
rs 
As few terms as 
possible are used to 
convey the concept 
(Parsimony) 
An existing 
deﬁnition is replaced 
only after 
ascertaining that a 
new deﬁnition 
would be superior 
(Consistency) 
An existing 
deﬁnition is not 
unnecessarily made 
less precise by 
expansion 
The concept is 
deﬁned without 
introducing new 
hypotheses 
√ √ √ √ 
√ 
N/A (3) N/A (3) 
√ 
√ 
N/A (3) N/A (3) 
√ 
√ 
N/A (3) N/A (3) 
√ 
√ 
N/A (3) N/A (3) 
√ 
✗ (5) N/A (3) N/A (3) √ √ 
N/A (3) N/A (3) 
√ 
✗ (5) N/A (3) N/A (3) ✗ (7) 
✗ (5) N/A (3) N/A (3) ✗ (7) √ 
N/A (3) N/A (3) ✗ (7) √ 
N/A (3) N/A (3) 
√ 
✗ (5) N/A (3) N/A (3) √ √ 
N/A (3) N/A (3) 
√ 
√ √ √ √ 
√ 
N/A (3) N/A (3) 
√ 
✗ (5) √ ✗ (5) √ 
✗ (5) N/A (3) N/A (3) √ 
✗ (5) √ √ √ √ √ √ ✗ (7) √ 
N/A (3) N/A (3) 
√ 
√ 
N/A (3) N/A (3) 
√ 
√ 
N/A (3) N/A (3) 
√ 
✗ (5) N/A (3) N/A (3) ✗ (7) √ 
N/A (3) N/A (3) 
√ 
✗ (5) N/A (3) N/A (3) √ √ 
N/A (3) N/A (3) 
√ 
√ 
N/A (3) N/A (3) 
√ 
✗ (5) √ ✗ (5) √ √ 
N/A (3) N/A (3) 
√ 
√ 
N/A (3) N/A (3) 
√ 
√ 
N/A (3) N/A (3) 
√ 
√ 
N/A (3) N/A (3) 
√ 
√ √ √ ✗ (7) √ 
N/A (3) N/A (3) 
√ 
✗ (5) N/A (3) N/A (3) √ √ 
N/A (3) N/A (3) 
√ 
√ 
N/A (3) N/A (3) 
√ 
✗ (5) N/A (3) N/A (3) ✗ (7) 
 the original rules has been omitted here since none of the examined works deals with 
not given speciﬁcally (E.g. does not read like: “The PSC is …”), and may not be presented 
onceptual deﬁnitions is made; 4 Focus on a speciﬁc medical supply; 5 Qualiﬁcations keep 
l supply chain; 7 Hypotheses embedded in deﬁnition (for example, cost-effective). N/A: ppendix B 
Table B.1. Evaluation of selected deﬁnitions of pharmaceutical s
onceptual deﬁnition. 
Deﬁnitions’ references Criteria ∗
The term deﬁned 
can be replaced by 
the words used to 
deﬁne it in a 
sentence and not 
have the sentence 
change meaning 
(Replacement) 
The concept is 
distinguished from 
seemingly similar 
concepts by 
excluding shared 
terms (Denotation 
matches 
connotation) 
Ambiguity is 
reduced by avo
terms such as 
or, and/or”, an
adding modiﬁe
(Clarity) 
Pharmaceutical 
Proposition 1 
√ √ √ 
Existing deﬁnitions 
[104] ✗ (1) ✗ (2) √ 
[70] ✗ (1) √ (4) √ 
[62] ✗ (1) √ √ 
[105] 
√ √ √ 
[68] 
√ √ ✗ (5) 
[45] 
√ √ √ 
[43] 
√ ✗ (2) ✗ (5) 
[42] ✗ (1) ✗ (2) √ 
[11] 
√ √ √ 
[51] 
√ √ √ 
[74] ✗ (1) √ √ 
[64] ✗ √ √ 
[35] 
√ √ √ 
[110] ✗ ✗ (6) √ 
[111] 
√ ✗ (2) ✗ (5) 
[113] 
√ ✗ (2) ✗ (5) 
[76] ✗ √ ✗ (5) 
[37] ✗ ✗ (2) ✗ (2) 
[118] ✗ √ √ 
[90] ✗ √ √ 
[91] ✗ (1) ✗ (2) √ 
[85] ✗ √ √ 
[61] ✗ (1) √ √ 
[121] ✗ (1) √ √ 
[122] ✗ (1) ✗ (2) √ 
[77] 
√ √ √ 
[39] 
√ √ √ 
[97] 
√ √ √ 
[125] 
√ √ √ 
Generic supply chain 
Review papers 
[34] 
√ √ √ 
[99] 
√ √ √ 
[38] ✗ √ √ 
[31] 
√ √ √ 
[41] ✗ √ ✗ 
[54] 
√ √ √ 
Textbooks 
[20] 
√ √ √ 
[127] ✗ ✗ √ 
Notes: 
∗ Adapted from the rules of good conceptual deﬁnition (Wacker, 2004). One of
the empirical testing of the concept of pharmaceutical supply chain; 1 Deﬁnition is 
in a consequential manner; 2 Adjacent concepts coexist; 3 No reference to existing c
being added; 6 Generic concepts used instead of speciﬁc concept of pharmaceutica
not applicable. 
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